DD Support Board and Research Team

[Zorax]

With this case, SEC enforcement actions involving whistleblower awards have now resulted in more than $1 billion in financial remedies ordered against wrongdoers.

Too bad the sec has collected to what amounts to 10% of what they paid out to whistleblowers. As the SEC has almost zero record for collections of the fines.

[Zorax]

I've also personally called GHS/ITOR and was given the same information regarding efficacy and antitumor activity in the Oncolix phase I trial for their drug Prolanta. These statements have also been made by the company before they ever went public, so they clearly weren't saying that to sell stock.

Speculation used to sell stock by 3rd parties, not directly from the companies, who don't want to reveal their involvement. Is there a link?

[dabullishbear]

Not true. Companies will note whether or not there has been efficacy observed in a Phase I trial. Check out the Novartis Phase I trial results for their drug LFA102. They noted as part of their results that there wasn't any efficacy or antitumor activity observed.

I've also personally called GHS/ITOR and was given the same information regarding efficacy and antitumor activity in the Oncolix phase I trial for their drug Prolanta. These statements have also been made by the company before they ever went public, so they clearly weren't saying that to sell stock.

And it wouldn't make sense not to check on whether or not a patients condition is improving when they are dying from a late stage ovarian cancer. These people may only have months to live, so obviously their doctors are going to be monitoring their cancer. If they notice during phase I that the patients are improving, they can conclude the phase I doses are showing efficacy.

[janice shell]

Beats me. But I'm not sure I see the sense of hundreds or thousands of different cryptocurrencies...

[Zorax]

This is what I meant by other bitcoin. What happened to the Saki concept of value to his limited bitcoin he created? I think this point alone may do more to bitcoins fail than almost anything else. How can one keep value if everyone else can create their own? The reason why the worlds different currencies have worked for centuries is because we can have a standard basic basis of value everyone can work with and plan for.

"Its fall on Thursday dragged down the prices of other cryptocurrencies in its wake, with Ethereum, bitcoin’s biggest rival, falling as much as 19 percent on the day, according to trade website Coinmarketcap."

[BadKarmaKyle]

Thank you, I would be inclined to agree. After doing some research I would advise anyone interested in investing in the Cannabis sector ignore this self proclaimed “guru” of Cannabis investing. Why? AB Touts PHOT in the $.40’s - Those who took his advice lose millions - AB Touts FITX - Those who took his advice lose millions - AB Touts MSRT in the $2.00’s - Those who took his advice lose millions - AB - Touts TRTC as 10% of his model portfolio and today advises add more. Simultaneously calling the company out as a massive insider enrichment scheme. The initial buy recommendation came in July 2015 when the price of TRTC was $.30. It closed yesterday at $.19 down 35% from his initial buy recommendation. The “guru” of Cannabis investing said he saw it going to $.70. Why would an analyst who dislikes a company advise putting 10% or more of your investment funds in it? What possible inducement makes him do this?

[scion]

More Than $16 Million Awarded to Two Whistleblowers

SEC Order
http://www.sec.gov/rules/other/2017/34-82181.pdf

FOR IMMEDIATE RELEASE
2017-216

Washington D.C., Nov. 30, 2017 —
The Securities and Exchange Commission today announced awards of more than $8 million each to two whistleblowers whose critical information and continuing assistance helped the agency bring the successful underlying enforcement action.

With this case, SEC enforcement actions involving whistleblower awards have now resulted in more than $1 billion in financial remedies ordered against wrongdoers.

The first whistleblower alerted SEC enforcement staff of the particular misconduct that would become the focus of the staff’s investigation and the cornerstone of the agency’s subsequent enforcement action. The second whistleblower provided additional significant information and ongoing cooperation to the staff during the investigation that saved a substantial amount of time and agency resources.

“Whistleblowers have played a crucial role in the progression of many investigations and the success of enforcement actions since the inception of the whistleblower program,” said Jane Norberg, Chief of the SEC’s Office of the Whistleblower. “The value of whistleblowers can be seen in the more than $1 billion in financial remedies ordered against wrongdoers based on actionable information from whistleblowers, including more than $671 in disgorgement of ill-gotten gains, much of which has been or is scheduled to be returned to harmed investors.”

The SEC’s whistleblower program has now awarded more than $175 million to 49 whistleblowers since issuing its first award in 2012. All payments are made out of an investor protection fund established by Congress that is financed entirely through monetary sanctions paid to the SEC by securities law violators. No money has been taken or withheld from harmed investors to pay whistleblower awards.

Whistleblowers may be eligible for an award when they voluntarily provide the SEC with original, timely, and credible information that leads to a successful enforcement action. Whistleblower awards can range from 10 percent to 30 percent of the money collected when the monetary sanctions exceed $1 million.

By law, the SEC protects the confidentiality of whistleblowers and does not disclose information that might directly or indirectly reveal a whistleblower’s identity.

For more information about the whistleblower program and how to report a tip, visit www.sec.gov/whistleblower.

###

https://www.sec.gov/news/press-release/2017-216

[Zorax]

Phase 1 trials are what Janice said they are for, and even the companies themselves do not take phase 1 data as any speculative investment vehicle and only the paid awareness campaign stock touts of scam pink companies use phase 1 as a misinformation device to sell stock.

[cayman_west]

He knows zip about the industry. (I am in the industry)

[surfkast]

Just be careful as Talari is a proven wife beater per police records.

[janice shell]

That might be fun...

[jet101]

I actually go to that area sometimes, maybe I'll stop by and say hello to them........LOL

[surfkast]

And I believe not one generated a profit.

[janice shell]

Yes, they've been busy...

[scion]

Bitcoin loses over a fifth of its value in less than 24 hours

Reuters Staff NOVEMBER 30, 2017 / 2:08 PM / UPDATED AN HOUR AGO 2 MIN READ
https://uk.reuters.com/article/uk-global-markets-bitcoin/bitcoin-loses-over-a-fifth-of-its-value-in-less-than-24-hours-idUKKBN1DU1YT?il=0

LONDON (Reuters) - Bitcoin slid to as low as $9,000 on Thursday, having lost more than a fifth of its value since hitting an all-time high of $11,395 on Wednesday..

The cryptocurrency fell as much as 8 percent on Thursday on the Luxembourg-based Bitstamp exchange to hit $9,000 exactly, marking a fall of well over $2,000 in under 24 hours. It then edged back up to trade at around $9,200 a few minutes later, still down over 6 percent on the day.

The fall tempers an astronomical rise for the cryptocurrency in recent months - bitcoin was up almost 1100 percent year-to-date on Wednesday. As of 1400 GMT on Thursday, it was still up around 850 percent.

Its rapid ascent has prompted warnings from a stream of prominent investors that it had reached bubble territory, while Bank of England deputy governor on Wednesday said investors should “do their homework” before investing in the digital currency.

Its fall on Thursday dragged down the prices of other cryptocurrencies in its wake, with Ethereum, bitcoin’s biggest rival, falling as much as 19 percent on the day, according to trade website Coinmarketcap.

For the month, bitcoin is still on track for a more than 40 percent price increase.

Reporting by Abhinav Ramnarayan; Editing by Jemima Kelly

https://uk.reuters.com/article/uk-global-markets-bitcoin/bitcoin-loses-over-a-fifth-of-its-value-in-less-than-24-hours-idUKKBN1DU1YT?il=0

[dabullishbear]

Yes that is true, but they did observe efficacy (anti-tumor activity) in the initial phase I human study. The drug was also well tolerated with no adverse effects. And because of the structure of the drug, they don't believe and they will be any dose limiting toxicities.

[dabullishbear]

The company was founded in 2006: https://oncolixbio.com/about/management-team/

https://www.crunchbase.com/organization/oncolix
http://www.bioworld.com/content/oncolix-seeks-funding-prolactin-antagonist-trials-0

The drug Prolanta or G129R has been researched and studied by its inventor, Wen Chen, who is also an advisor to Oncolix, since 1999: https://www.ncbi.nlm.nih.gov/pubmed/10589775

https://www.ncbi.nlm.nih.gov/m/pubmed/11894130/
https://www.ncbi.nlm.nih.gov/pubmed/14647416


This is a report published in 2014 about the clinical studies/trials that were conducted on xenograft mice:
http://www.sciencedirect.com/science/article/pii/S2211124714001879

Video interview with Michael Redman:

Another article about Oncolix raising money: https://bionews-tx.com/news/2015/01/28/oncolix-raises-4-2-million-study-cancer-therapy-tetf-help/

ITOR/GHS is where they are doing their clinical trials, note that they are one of the highlighted companies along side Amgen, AstraZeneca, Eisai Pharmaceuticals, and Novartis: http://www.itor-ghs.org/pharmaceutical-industry.php

Also, in that S-1/A filing, those shares are being distributed to all of the owners and investors of Oncolix when the company was private. Oncolix is more than 70% institutional ownership. Greenville Health System, Texas Treasury Safekeeping Trust, Biovectra, Integrium. The most recent financing in that S-1/A is a private placement with companies Newbridge Securities Corporation and LifeTech Capital.

[loanranger]

??? "Shares of our common stock issuable upon the exercise of stock options exercisable currently or within 60 days of xxxxxxx x, 2017 are deemed outstanding and to be beneficially owned by the person holding such option for purposes of computing such person’s percentage ownership, but are not deemed outstanding for the purpose of computing the percentage ownership of any other person".

That's standard language in the 10-K's SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT section.
Would options exercisable at a dime be considered "options exercisable currently" if the shares were selling for a penny at the relevant date and the options unlikely to be exercised?

[jet101]

Here are a few of their ventures together over the years.

https://www.corporationwiki.com/Florida/Seminole/karin-rohret/99061689.aspx

[namtae]

Correct..

The primary endpoints of this Phase 1 study is to determine safety & dosing. However, many clinicals will report on evidence of efficacy if its observed.. Phase 2 is where efficacy & side effects are the primary endpoints.

[leftovers]

Ya amazing seems like penny stocks are now climbing on board to use this in the latest way to Scam? Like oil and gold in the old days.

INTV has popped up on radar and is trading like crazy off this Bitcom rush!

lots of red flags:

Recent RS and change of business venue !

Steve E Rubakh Owner Ceo has a Insider filling showing him with 54 million shares 14 more than are authorized! All purchased at .0012 or below!

Posting on the board is elevating to cult levels!

Steve has possible criminal records?

Old time Marks posting on the board claiming pie in the sky chants!

WEB site makes ya shake your head and go ya Right!

Rapid fire Pr's hitting the street!

Stock just ran from low pennies to .90 with the cult chanting 10 dollars!

Have I missed something or is Bitcom going to be the next wave of penny scams. Of course I could be wrong and Steve could be legit but something tells me this INTV sticks of Scam!

[integral]

We don't DD posters, just companies and their respective execs. Send 420 a PM. Since you are a free account you can do that for free on Friday for an hour after the close.

[BadKarmaKyle]

Does anyone have DD on the 420 Investor guy who calls himself the “guru” of DD in Cannabis investing? He calls out TRTC for being an “insider enrichment scheme” yet simultaneously holds 10% of his model portfolio in TRTC. Today he advises add more. What could possibly “induce” him to do so?

[zen222]

Usually that is correct but they have evidence of tumor reduction in this phase. The company has yet to quantify the efficacy but it's being claimed by folks doing the study at Greenville Health System. That preliminary data is one of the catalysts shareholders are looking forward to.

[janice shell]

As I understand it, Phase I trials only determine that the drug won't harm humans who may take it. Efficacy is not addressed.

Phase 1 studies are usually conducted in healthy volunteers. The goal here is to determine what the drug's most frequent side effects are and, often, how the drug is metabolized and excreted. The number of subjects typically ranges from 20 to 80.

https://www.fda.gov/drugs/resourcesforyou/consumers/ucm143534.htm

[zen222]

Oncolix's phase 1 clinical trial for Prolanta began in 2016.

I thought this was supposed to be a DD board.

[Zorax]

And still in stage 1 development?
Hey, n-t-ek the world leader in 4K content, an even bigger company than netlfix and the exclusive media provider of ALL paramount content ever created is still a stage 1 company going on... ah, 11 years I think.

So anythings possible.

[Huggy Bear]

And still in stage 1 development?

[N4longterm]

Yet another post claims started in 2006....

Must be that 'New Math'.

[Diogenes of Sinope]

The St. Petersburg shell factory;

https://scontent.fyto1-1.fna.fbcdn.net/v/t1.0-9/fr/cp0/e15/q65/13418723_1107319199328427_8225192022417346128_n.jpg?efg=eyJpIjoidCJ9&oh=f08513b529b626113a2eca58d51412ce&oe=5AD54D58

Contact Info
10901 Roosevelt Blvd
1000c
Saint Petersburg, FL 33716

[surfkast]

All of Talari's shells are run out of St. Pete!

[integral]

Thanks, I don't always read every post.

I will look further.

[zen222]

This was the original request: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=136502007

It was an attempt to shut down a couple of posters with their baseless & absurd claims of "fake drug", "failed drug", "fake company", "fake merger", "empty shell scheme", "fraud", "scam", "pyramid scheme", "criminal activities", "CEO is a criminal soon to be jailed", the list of nonsense goes on.
The S-1 is nothing new, everyone knows about the debt and it was never really an issue up for debate.

Anyhoo, I don't expect anyone to go out of their way to disprove the ridiculous posters trolling the board but it was worth a shot. Looking for a fraud squad seal of legitimacy was too much to ask for.
Have a good night, I'm done for now.

[Zorax]

Where is a clinical stage drug startup company going to get income from

So, you're stating this company is a 18+ years of research and development start-up stage company for um, 18+ years?

[janice shell]

I don't know a thing about Ethereum or any of the others...

[Zorax]

Yes, his issuance. I'm commenting on everyones else new created issuance of bitcoin. I don't think you can call etherim or whatever that and the others are called being attached to Saki.

[integral]

What DD are you looking for? My spouse has spent years through clinical trials, 500 plus patents and tens of thousands of pages of actual B-Plan and Valuation models, raised $100's of millions.

I Will ask, if you are more specific. My spouse is no longer in the bio industry, and is not competitive with your stock.

For now, the S-1 on an underfunded OTC stock is speculative at best, inclusive of a working capital deficit.

[janice shell]

Probably more than that, unfortunately.

[Crazy Money]

I could have TOLD ya'll IFXY was in St. Pete... zzz

[zen222]

No, you obviously don't understand the nature of the DD request.
You are right, there is debt. That was NEVER the issue.
And the thanks anyway was just me being polite because you've offered nothing new to the conversation. Again, no one asked for any clarification of the S-1. This was all about false claims by a few posters on the board that the reverse merger was somehow "fake" and that a drug still in phase 1 trial had somehow already "failed" and other such nonsense. Oncolix is a clinical-stage biopharma company, to my knowledge, it's rare for companies like ONCX not to be in debt. Just looking at one filing isn't the DD support we were looking for.

[dabullishbear]

I'm not BSing you. Have you done any research into this company beyond S-1/A?

They've been in business since 2006. They raised between $15m-$20m in venture capital to fund their operations up until this year. They have the backing of the Texas Treasury Safekeeping Trust and Greenville Healthcare System. Mario Ernest Glaxo the former CEO of Glaxo Smith Kline GSK is an investor here.

They have 34 US and international patents for their drug Prolanta. They have already shown promising results in xenograft studies and in the first set of human trials in Phase I which they are looking to continue.

Prolanta Science:

Wen Chen (Prolanta Inventor)

He also invented Somavert which is known as G120R. Somavert was successfully brought through trials obtaining FDA approval and is now sold on the market by Pfizer. Somavert (G120R) is a growth hormone receptor antagonist. This drug was able to successfully inhibit growth hormone receptors to help patients who have growth hormone disorders.

Prolanta also known as G129R is Wen Chens other invention. He developed both G120R and G129R around the same time period using the exact same amino acid substitution method. These drugs are almost identical to each other. The other interesting fact is that the structure of prolactin is similar to that of growth hormone and placental lactogen.

So here you have 2 identical drugs that are antagonists for 2 hormones that are very structurally similar to each other. Inhibiting human prolactin may be effective in antitumor activity because of its role in the presence and growth of cancerous tumors. The other issue with human prolactin hormones is that they also contribute to humans becoming resistant to chemotherapy. If you can antagonize the human prolactin receptors and hormone, you can at the very least increase the efficacy of chemotherapy, which in itself would be a major breakthrough.

So in conclusion, knowing that we have 2 almost identical drugs working to antagonize structurally similar hormones, we can hypothesize that both would be almost equally effective. One drug, Somavert, has already achieved FDA approval, and the other drug, Prolanta, has a strong probability to follow suit.

Here's an article that contains information regarding the similarities of the prolactin hormone and growth hormone:

https://link.springer.com/chapter/10.1007%2F978-1-4757-3600-7_7

They are both pituitary hormones with structural similarities. Somavert was able to become a successful antagonist to HGH and Prolanta is a nearly identical drug and will more than likely be a successful antagonist to PRL.

Successful antagonism of PRL doesn't guarantee antitumor activity as a monotherapy, but knowing PRL's role in cancer patients resistance to chemo, it's almost guaranteed to improve the efficacy of the chemo, which would be a major breakthrough.

What we do know, based on what Redman has said and also what Lisa Johnson told me over the phone when I called GHS/ITOR, is that Prolanta, as a monotherapy, is showing efficacy.

[integral]

No company in clinical trials sits with $15k in tangible assets and registers stock to insiders. This is not a secondary offering to investors or institutions.

If they want to raise capital for clinical trials, register $100 million and raise capital, not let insiders sell out.

[integral]

Hmm, I have a family member whom has passed from Ovarian Cancer. Further, I have a family member whom has worked on clinical trials for cancer, funded by me and Canaccord and traded on the ASX. Don't BS me. This sits home.

[dabullishbear]

Where is a clinical stage drug startup company going to get income from? They aren't in any different of a position than the 100's of Nasdaq biopharma's who are clinical stage. At this point, all these companies have are costs and no way to generate revenue until they can gain an FDA approval and bring a drug to market. The cost manufacturing drugs and clinical trials is in the millions. What are they supposed to do?

There is nothing out of the ordinary with Oncolix.

[dabullishbear]

What's sad about a company raising money in order to continue their phase I trials for women who have late stage ovarian cancer? How else are they going to get money to continue operations? I have yet to hear one person come up with a better alternative.

Should they just scrap the 18+ years of research and development on a promising cancer treatment because of some unfavorable financing? Seriously, what should they have done differently?

[integral]

No"no to what"?, and you are right Right about what? about that. Oncolix was originally brought up here because of baseless claims by a few posters of “fake merger,” “failed product,” and “criminal activity” by the company or any of its current officers, board members and/or company advisors. Curious about claims from officers, BoD and :advisors"The notes and future conversion was never an issue but thanks anyway. Registering shares in the amount of $3million when the company has a working capital deficit and only $15,000 in tangible assets is a "thanks anyway"?

Most investors have more that $15,000 laying around and far less than $2.5 million in debt.

Valuation here is a problem at best.

[integral]

Yep, that is where I pulled my info from. Sad state of affairs.

[Homebrew]

ONCX Form S-1/A posted today.
https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=12404073

[Homebrew]

FCRD imploded yesterday/today after getting skull & bones. By the sounds of it, a lot of flippers are stuck with bags of shares.

[zen222]

No, and you are right about that. Oncolix was originally brought up here because of baseless claims by a few posters of “fake merger,” “failed product,” and “criminal activity” by the company or any of its current officers, board members and/or company advisors. The notes and future conversion was never an issue but thanks anyway.